Related Articles
Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16.
Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF
Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I− tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines
Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy
NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours